about
Probiotics promote gut health through stimulation of epithelial innate immunity."Mucosal healing" in ulcerative colitis: Between clinical evidence and market suggestion.Safety considerations when using anti-TNFα therapy to treat Crohn's disease.Natalizumab in the treatment of Crohn's disease patients.Endoscopic scores for inflammatory bowel disease in the era of 'mucosal healing': Old problem, new perspectives.Proposal of a new clinical index predictive of endoscopic severity in ulcerative colitis.Outcome and risk of recurrence for endoscopic resection of colonic superficial neoplastic lesions over 2 cm in diameter.IL-1beta-511 and IL-1RN*2 polymorphisms in inflammatory bowel disease: An Italian population study and meta-analysis of European studies.Administration of two anti-TNFα agents in an ulcerative colitis patient with HBV-related cirrhosis.Development of an Ex Vivo Organ Culture Technique to Evaluate Probiotic Utilization in IBD.Letter: investigating the intestinal mucosa-associated microbiota - relevance and potential pitfalls.Elevated C-Reactive Protein in Asymptomatic Crohn's Disease Patients: Listen to the Sound of Silence.Searching for biomarkers in clinical practice: the prevalence and clinical significance of hypergammaglobulinemia in inflammatory bowel disease patients.Systematic Review with Network Meta-Analysis: Efficacy of Induction Therapy with a Second Biological Agent in Anti-TNF-Experienced Crohn's Disease Patients.Comparison of three different risk scoring systems in non-variceal upper gastrointestinal bleedingAlteration of local microflora and α-defensins hyper-production in colonic adenoma mucosaCARD15 and Toll-like receptor 4 mutations in Italian patients with inflammatory bowel diseaseCutaneous manifestations and gastrointestinal disorders: Report of two emblematic casesDisease Extension Matters in Endoscopic Scores: UCEIS Calculated as a Sum of the Single Colonic Segments Performed Better than Regular UCEIS in Outpatients with Ulcerative ColitisSimilar But Not Identical: Plaque Psoriasis Exacerbation in a Patient With Crohn's Disease After Switching From CT-P13 to SB2 Infliximab BiosimilarDiet Supplementation, Probiotics, and Nutraceuticals in SARS-CoV-2 Infection: A Scoping Review
P50
Q30437282-8D5EC30E-5E93-4765-964D-B486D8CF0937Q38217234-89D47B41-6175-4077-BEF8-AB2CC46C8842Q38268598-A1E2BBB7-B98D-40E1-97AC-6C2A2AED8E0EQ38612843-FBC1412E-7415-4699-83FB-7D97179ADE4AQ38799676-E2ACA5B2-843C-476C-990D-8967C1CB745AQ40513791-9C1AA8BA-D0E4-441C-A103-0B07C63185D4Q40940730-F6792250-A6F6-4B06-809D-568E9A51E525Q43964494-70771325-82DA-427C-8710-CE897BCEDA3BQ44807268-8ECAEA64-F2D5-4E8F-A669-C8F1F5333E8CQ46478046-22414C7B-AFFA-4F83-A3BC-E1A965AAD30FQ46503556-5C7F5102-0481-4295-8455-9E2137E08C8FQ51158556-59E4FCC0-0164-4478-92F8-738149C35823Q51258781-B9ECFED0-99BE-4B79-815E-9FE9B2DB3A87Q64901646-D5403173-C9E8-4221-9F4A-3E1E8ED7B8AEQ80018670-DBC1C199-1FA5-43B4-898E-0023889BDBE8Q83466615-91629266-EFD4-44F8-9DDD-F72DC48C5AB1Q84096347-5752A987-3A9E-49AF-94FC-7E8AC1DCF9FDQ86178062-0BD6F57A-D616-4701-A0CC-D71ED2674D54Q87311009-5930C2F6-2E20-4467-83FC-A5A6BA94D53FQ95849672-7BB7F674-4AD1-44B7-82FA-30F4E1AE33FEQ96294830-6C825682-01D0-470E-8644-D00E17B96457
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Cristiano Pagnini
@ast
Cristiano Pagnini
@en
Cristiano Pagnini
@es
Cristiano Pagnini
@nl
type
label
Cristiano Pagnini
@ast
Cristiano Pagnini
@en
Cristiano Pagnini
@es
Cristiano Pagnini
@nl
prefLabel
Cristiano Pagnini
@ast
Cristiano Pagnini
@en
Cristiano Pagnini
@es
Cristiano Pagnini
@nl
P106
P1153
16316752700
P21
P31
P496
0000-0001-9985-7490